Section 16-3200. CLASSES OF INFRACTIONS

 

3200.1The schedule of fines set forth in this chapter shall include the following classes:

 

(a)Class 1 - Egregious infractions that result from flagrant, fraudulent, or willful conduct, or unlicensed activity, or that are imminently dangerous to the health, safety, or welfare of persons within the District of Columbia;

 

(b)Class 2 - Other serious infractions that result from flagrant, fraudulent, or willful conduct, or unlicensed activity, or that are imminently dangerous to the health, safety, or welfare of persons within the District of Columbia;

 

(c)Class 3 - Infractions that involve a failure to comply with a law or rule requiring periodic renewal of licenses or permits, or infractions that are serious and have an immediate, substantial impact on the health, safety, or welfare of persons within the District of Columbia;

 

(d)Class 4 - Infractions that involve a failure to post required licenses or permits, or infractions that are minor, but have the potential to be hazardous to the health, safety, or welfare of persons within the District of Columbia; and

 

(e)Class 5 - Infractions that collectively create a nuisance but individually do not pose a threat to the health, safety, or welfare of persons within the District of Columbia.

 

(f)Class 6 – Infractions that involve the purchase, sale, exchange, or any other form of commercial transaction involving the sale of a synthetic drug in violation of D.C. Official Code § 47-2844(a-2)(1A).

 

3200.2The schedule of fines may also include infractions that have not been classified in accordance with § 3200.1.

 

 

authority

Sale of Synthetic Drugs Amendment Act of 2016, effective February 18, 2017 (D.C. Law 21-0215; 63 DCR 15708 (December 23, 2016)).

source

Final Rulemaking published at 46 DCR 6017 (July 23, 1999); as amended by Final Rulemaking published at 47 DCR 4617 (August 4, 2000); as amended by Final Rulemaking published at 47 DCR 6892 (August 25, 2000); as amended by Final Rulemaking published at 47 DCR 8091 (October 4, 2000); as amended by Final Rulemaking published at 47 DCR 9677 (December 8, 2000); as amended by Final Rulemaking published at 48 DCR 6656 (July 27, 2001); as amended by Final Rulemaking published at 48 DCR 7212 (August 3, 2001); as amended by Final Rulemaking published at 50 DCR 990 (January 31, 2003); as amended by Final Rulemaking published at 50 DCR 1514 (February 14, 2003); as amended by Final Rulemaking published at 51 DCR 7394 (July 30, 2004); as amended by Final Rulemaking published at 52 DCR 4903 (May 27, 2005); as amended by the Sale of Synthetic Drugs Amendment Act of 2016, effective February 18, 2017 (D.C. Law 21-0215; 63 DCR 15708 (December 23, 2016)).